Participated · Seed · Nov 2025

Cordance Medical is building a noninvasive focused ultrasound system designed to temporarily and safely open the blood-brain barrier (BBB), enabling drugs and other therapeutic agents to reach the brain more effectively. The platform employs patient-specific signal processing with real-time monitoring of BBB opening and avoids the need for head fixation or live imaging, targeting practical outpatient use. While its first clinical application is brain cancer, the company envisions broader utility across multiple neurological conditions. Cordance has already secured FDA Breakthrough Device Designation in neuro-oncology and received a grant from the National Cancer Institute at the NIH to help fund its first-in-human U.S. trial. Proceeds from its recent seed financing will advance this clinical study and further product development. Based in Mountain View, California, the firm is supported by a strong syndicate of healthcare and neuro-oncology investors. The company has not disclosed revenue, user numbers, or other operating metrics.

Participated · Seed · Nov 2025

Founded in 2022 by Cambridge-trained researchers Ben Woodington and Elise Jenkins, San Francisco–based Coherence Neuro decodes the body’s electrical patterns to understand and correct disease states. Its flagship device, SOMA-1, continually records neural activity and delivers precise stimulation, creating a bi-directional, closed-loop therapy that aims to nudge tumorous tissue back toward healthy function. Each deployed device feeds data into what the company calls the world’s largest disease-focused dataset, allowing the system to learn and improve with every patient. Coherence frames cancer as a system-level error rather than an external invader, seeking to replace aggressive treatments like surgery and chemotherapy with continuous, gentler neuromodulation. The company plans to begin first-in-human trials next year, using its newly secured capital to validate safety and efficacy. To date, it has raised a $10 million seed round to fund these efforts and further develop its data-driven platform.

Participated · Seed · Sep 2020

Britive provides a platform for cloud identity and access management that generates access privileges (tokens and keys) on demand and automatically expires them when not in use. The product analyzes cloud user activity logs in near real time with anomaly‑spotting AI and alerts security teams, enabling rapid termination of problematic sessions. Britive says its platform manages thousands of daily active privileged identities interacting with critical cloud applications and infrastructure. CEO Art Poghosyan says annual recurring revenue is in the “millions” and growing roughly 3x year over year, and the company now serves “dozens” of customers, including several Fortune 500 brands. The company currently has about 55 employees and expects to add 10–20 staffers by year end. Raised funds will be used to expand customer success, marketing and sales, and product development. Britive provides an automated, policy-driven privileged access platform that grants just-in-time permissions to both humans and machine identities across multiple cloud vendors and software services. The product covers a range of access forms including API keys, secrets, and permissions needed by automation tools like Terraform and CI/CD systems such as GitHub. CEO Art Poghosyan emphasizes moving organizations away from statically granted access toward time-limited, policy-based access. The company launched in 2018, brought its first product to market in 2019, and is based in Los Angeles. Britive currently has 40 employees and says it will use the new capital to double headcount over the next 12 months; it also highlights that over 50% of its current workforce comes from ethnic minority groups. Financially, the company has raised a $10M Series A on top of a $5.4M seed, bringing total disclosed funding to approximately $15.4M. Britive provides cloud-native security solutions that deliver control over access privileges, including patent-pending technology for dynamic, time-limited privilege elevation on a pre-authorization basis. Its intelligent engine learns user behavior, recommends privilege right-sizing for users and machine IDs, and constantly monitors for anomalies indicating privilege misuse. The platform targets cloud-forward enterprises and is used by medium to large businesses and Fortune 500 customers across healthcare, automotive, retail, media & entertainment, and other industries. The company plans to further develop its platform technology for monitoring, analyzing, and dynamic orchestration of access privileges. Britive also intends to expand its go-to-market capabilities using the new funding. The product is positioned to reduce risk from over-privileged accounts and automate administrative access workflows.